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ABSTRACT
Objective To analyse the impact of postprocedural
mitral regurgitation (MR), in an interaction with aortic
regurgitation (AR), on mortality following transcatheter
aortic valve implantation (TAVI).
Methods To assess the interaction between MR and
AR, we compared the survival rate of patients (i) without
both significant MR and AR versus (ii) those with either
significant MR or significant AR versus (iii) with
significant MR and AR, all postprocedure. 381
participants of the Polish Transcatheter Aortic Valve
Implantation Registry (166 males (43.6%) and 215
females (56.4%), age 78.8±7.4 years) were analysed.
Follow-up was 94.1±96.5 days.
Results Inhospital and midterm mortality were 6.6%
and 10.2%, respectively. Significant MR and AR were
present in 16% and 8.1% patients, including 3.1%
patients with both significant MR and AR. Patients with
significant versus insignificant AR differed with respect
to mortality (log rank p=0.009). This difference was not
apparent in a subgroup of patients without significant
MR (log rank p=0.80). In a subgroup of patients
without significant AR, there were no significant
differences in mortality between individuals with versus
without significant MR (log rank p=0.44). Significant
MR and AR had a significant impact on mortality only
when associated with each other (log rank p<0.0001).
At multivariate Cox regression modelling concomitant
significant MR and AR were independently associated
with mortality (OR 3.2, 95% CI 1.54 to 5.71, p=0.002).
Conclusions Significant MR or AR postprocedure,
when isolated, had no impact on survival. Combined MR
and AR had a significant impact on a patient’s
prognosis.
INTRODUCTION
Mitral regurgitation frequently coexists with aortic
stenosis. Its presence is associated with increased
surgical risk and a worse long-term outcome in
patients undergoing aortic valve replacement.1
There seems to be little doubt that preprocedural
mitral regurgitation adversely impacts prognosis in
transcatheter aortic valve implantation (TAVI)
patients as well.2 However, in some patients, the
severity of mitral regurgitation is reduced following
TAVI.3 Data concerning the potential clinical
benefit of such an improvement with long-term
follow-up are more limited.2 Recently, Khawaja
et al4 demonstrated that mitral regurgitation wor-
sening is associated with a poorer survival rate.
Persistent or even worsening significant mitral
regurgitation may be especially important in
patients who develop a significant paravalvular leak
following TAVI, leading to additional volume over-
load and making these patients vulnerable to
haemodynamic decompensation. However, the
impact of this adverse interaction between mitral
and aortic regurgitation on survival rates following
TAVI has not yet been separately studied.
The Polish Transcatheter Aortic Valve
Implantation Registry (POL-TAVI) 2013 included
105 patients qualified for TAVI with significant
mitral regurgitation. This provided an opportunity
to supplement existing data concerning the impact
of preprocedural and postprocedural mitral regurgi-
tation on mortality following TAVI and its inter-
action with aortic regurgitation.
METHODS
POL-TAVI is an obligatory prospective registry of all
patients undergoing TAVI in Polish hospital centres.5
The registry database contains detailed demographic
and clinical characteristics, results of imaging studies
including echocardiography and CT, laboratory
assessment, procedural results and the results of a
short-term and midterm follow-up (1 month,
6 months and 1 year). The current analysis included
patients who underwent TAVI in the year 2013,
regardless of the access site and valve type.
Echocardiographic study
Transthoracic echocardiographic studies were per-
formed prior to the procedure, immediately post-
procedure and at a 1-month follow-up. Mitral
regurgitation assessment involved assessment of mul-
tiple indices including valve morphology, colour
Doppler and continuous-wave Doppler of the regur-
gitant jet, vena contracta width, regurgitant volume
and effective orifice area (when available), according
to current guidelines.6 7 Mitral regurgitation was
considered ‘significant’ if graded as moderate (grade
3) or severe (grade 4). Changes in mitral regurgita-
tion severity were assessed between the baseline
study, postprocedure and at a 1-month follow-up.
They were classified as improvement/no change and
worsening of mitral regurgitation by at least one
grade. Paravalvular aortic regurgitation was graded
according to the Valve Academic Research
Consortium (VARC)-2 criteria.8
The follow-up period was defined from the date
of the procedure to either death or the last avail-
able follow-up visit. The primary end-point was
death from any cause. Mortality data were obtained
from the clinical follow-up data or from the
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National Statistics Office (PESEL system, PL), when necessary.
Statistical analysis
Statistical analysis was performed by SPSS V 17.0 (IBM,
New York, USA). The results were presented as mean (±SD) or
median (range). Differences among the groups were assessed
with Student’s t or Wilcoxon tests. Survival curves were created
using the Kaplan–Meier method for the following subgroups
with: (i) insignificant versus significant mitral regurgitation at
baseline, (ii) immediately postprocedure and (iii) at a 1-month
follow-up, as well as for subgroups of patients with (iv) no
change versus improvement versus worsening of mitral regurgi-
tation at a 1-month follow-up, compared with the baseline study.
To assess the interaction between the presence of aortic and
mitral regurgitation, we compared the survival of patients (i)
without significant mitral and aortic regurgitation versus (ii)
those with either significant aortic or significant mitral regurgita-
tion alone versus (iii) those with both significant mitral and
aortic regurgitation postprocedure.
Univariate Cox proportionate hazards modelling was per-
formed for each covariate using an unadjusted model.
Subsequently multivariate models using a forward elimination
method and entry criteria of p≤0.05 were constructed.
The study complied with the Declaration of Helsinki, and the
Institutional Ethics Committee of the Institute of Cardiology
approved the research protocol. Patients gave oral informed
consent to participate in the registry.
RESULTS
In the year 2013, 381 patients were enrolled in the POL-TAVI
registry following the TAVI procedure, including 166 males
(43.6%) and 215 females (56.4%) aged 78.8±7.4 years (range
35–85 years). A Medtronic CoreValve prosthesis was implanted
in 209 patients (54.9%), Edwards-Sapien XT in 133 (34.9%)
patients, Edwards-Sapien in 2 patients (4.5%) and other valve
types in 22 patients (5.8%). The follow-up period was 94.1
±96.5 days. Inhospital and overall mortality were 6.6% and
10.2% (25 and 39 patients, respectively). The demographic and
clinical data are presented in table 1 and baseline echocardio-
graphic characteristics in table 2.
Significant (grade 3 or 4) mitral regurgitation was present in
27.6% at baseline examination, in 16% of patients prior to dis-
charge, in 8.7% of patients at a 1-month follow-up and in 2.9%
of patients at a 6-month follow-up (p≤0.0001 for all vs base-
line). Changes in the mitral regurgitation grades during
follow-up are presented in figure 1.
Patients with a Medtronic CoreValve prosthesis had a greater
degree of mitral regurgitation prior to discharge than patients
with the Edwards-Sapien or Edwards-Sapien XT valves (2.0
±0.8 vs 1.8±0.7, p≤0.005). The same pertained to paravalvular
aortic regurgitation (1.7±0.6 vs 1.5±0.6, p≤0.01).
Significant mitral regurgitation at different time points and
mortality
Kaplan–Meier analysis revealed that patients with significant
versus insignificant preprocedural mitral regurgitation did not
differ with respect to mortality (log rank Mantel–Cox p=0.10)
(figure 2A). There were significant differences in mortality
however when preprocedural mitral regurgitation deteriorated
versus remained unchanged or improved at the 1-month
follow-up (log rank Mantel–Cox p=0. 048) (figure 2B).
Regardless of preprocedural mitral regurgitation, significant dif-
ferences in mortality were apparent in patients with significant
versus insignificant mitral regurgitation postprocedure and at
the 1-month follow-up (log rank Mantel–Cox p=0.02 and
p=0.003, respectively) (figure 2C, D).
Interaction between mitral regurgitation and aortic
regurgitation postprocedure
Thirty-one patients (8.1%) had significant aortic regurgitation
postprocedure including 12 patients with both significant mitral
and aortic regurgitation (3.1%). Patients with significant versus
insignificant aortic regurgitation, immediately postprocedure,
differed significantly with respect to mortality (log rank
Mantel–Cox p=0.009) (figure 3A). This difference was no
longer apparent when a subgroup of patients without significant
mitral regurgitation postprocedure was selected (log rank
Table 2 Baseline echocardiographic characteristics
Aortic valve area, cm2 (SD) 0.67 (0.18)
Peak aortic gradient, mm Hg (SD) 81.9 (27.2)
Mean aortic gradient, mm Hg (SD) 53.1 (20.1)
Left ventricular ejection fraction, % (SD) 52.4 (12.2)
Right ventricular systolic pressure, mm Hg (SD) 46.5 (15.10)












Table 1 Baseline demographic and clinical characteristics
Age, years (SD) 78 75±7,4
Male sex, n (%) 166 (43.6)
Logistic EuroSCORE (SD) 19.8 (14.3)





Significant coronary artery disease, n (%) 122 (31.9)
Prior myocardial infarction, n (%) 100 (26.2)
Prior CABG, n (%) 77 (20.2)
Prior PCI (last 12 months), n (%) 96 (25.2)
Prior aortic balloon valvuloplasty, n (%) 9 (2.4)
Prior cerebrovascular disease, n (%) 51 (13.4)
Chronic obstructive pulmonary disease, n (%) 63 (16.5)
Creatinine >200 μmol/L, n (%) 27 (7.1)
Atrial fibrillation, n (%) 132 (34.6)
Diabetes, n (%) 139 (36.5)
Prior pacemaker, n (%) 51 (13.4)
Pulmonary hypertension, n (%) 66 (17.3)
Multimorbidity, n (%) 257 (67.5)
Porcelain aorta, n (%) 45 (11.8)
Chest deformity, n (%) 12 (3.1)
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.















Mantel–Cox p=0.80) (figure 3B). Similarly in a subgroup of
patients without significant aortic regurgitation postprocedure,
there were no significant differences in mortality between indivi-
duals with versus without significant mitral regurgitation post-
procedure (log rank Mantel–Cox p=0.44) (figure 3C).
Significant mitral and aortic regurgitation postprocedure had a
significant impact on mortality only when associated with each
other (log rank Mantel–Cox p<0.0001) (figure 3D).
Cox regression analysis
Univariate Cox regression analysis revealed that preprocedure
mitral regurgitation had no significant association with mortality
(OR 1.71, 95% CI 0. 91 to 3.23, p=0.10). Factors significantly,
and at borderline significance, associated with mortality in the
overall population at univariate Cox proportionate hazards
modelling are presented in table 3.
At multivariate Cox regression modelling in the overall group
concomitant significant mitral and aortic regurgitation postpro-
cedure and EuroSCORE II were independently associated with
mortality (OR 3.21, 95% CI 1.54 to 5.71, p=0.002 and OR
1.07, 95% CI 1.02 to 1.11, p=0.003).
DISCUSSION
The current study demonstrated that there was a significant
interaction between the presence of a paravalvular leak follow-
ing TAVI and persistent mitral regurgitation. Of practical
importance, while there was a significant difference in mortality
between patients with significant versus insignificant aortic
regurgitation immediately postprocedure, this difference was no
longer apparent in a subgroup of patients without significant
mitral regurgitation postprocedure. Conversely, significant mitral
regurgitation, as expected, had an impact on mortality, but this
difference was not apparent in a subgroup of patients without
significant aortic regurgitation. Concomitant significant mitral
and aortic regurgitation postprocedure led to a sevenfold
increase in mortality, independently of other risk factors.
The incidence of paravalvular aortic regurgitation is decreas-
ing, but is still substantial. It has been identified as an independ-
ent risk factor of short-term and long-term mortality.9 While
some authors suggest that the risk attributed to a paravalvular
aortic regurgitation may be in part related to confounding
factors, volume overload caused by a regurgitant jet should not
be ignored. The interaction with mitral valve function was
demonstrated by Hayashida et al10—significant paravalvular
leaks were associated with the lack of regression or even further
aggravation of mitral regurgitation. In such circumstances, the
harm resulting from combined volume overload may clearly
prevail over the benefits of pressure overload correction with
TAVI.
Management of significant mitral regurgitation in patients
with severe aortic stenosis is a challenge. Since significant mitral
regurgitation is associated with increased perioperative risk and
worse long-term survival, some authors recommend double-
valve replacement/repair.11 The benefit of mitral valve repair
with aortic valve surgery was demonstrated, for example, by
Coutinho et al12 who reported that patients who underwent
combined mitral and aortic valve surgery experienced more pro-
nounced reverse left ventricular remodelling and greater clinical
benefit (New York Heart Association functional (NYHA) func-
tional classes III to IV). The lack of improvement in mitral
regurgitation severity in patients who underwent isolated aortic
valve surgery was associated with nearly fivefold increase in late
mortality. We observed greater mortality only in patients in
whom mitral regurgitation deteriorated. In the propensity-
Figure 1 Mitral regurgitation (MR) grades preprocedure, postprocedure and at a 1-month follow-up.















matched analysis of patients with significant mitral regurgitation
performed by McCarthy et al13, patients undergoing double-
valve surgery and TAVI had comparable perioperative outcomes.
However, as expected, mitral regurgitation was more signifi-
cantly reduced in surgical than TAVI patients and midterm sur-
vival was better in surgical patients. Given these considerations
in the cornerstone Placement of Aortic Transcatheter Valve
(PARTNER) trial, which laid the ground for the percutaneous
TAVI, concomitant significant mitral regurgitation constituted
one of the exclusion criteria.14 Nevertheless, a subgroup of
patients with significant mitral regurgitation was also included
in the PARTNER trial and its presence was associated with a
doubling of 30-day mortality.15
Presently, an increasing number of high-risk patients with
aortic stenosis and concomitant mitral regurgitation undergo
TAVI beyond classical indications.16 The decisions to intervene
in one or both valves in high-risk patients with aortic stenosis
and concomitant mitral regurgitation involve a quadruple choice
between single-valve, double-valve surgery, isolated TAVI and
TAVI with sequential/simultaneous percutaneous mitral valve
intervention in selected patients.17 The decisions are usually
based on the assessment, mitral valve morphology and function
as well as the probability of mitral regurgitation improvement
after isolated aortic valve intervention.18
However, the prediction of mitral regurgitation improvement
following TAVI is somewhat elusive. The results of clinical
observations are conflicting and a reproducible set of factors
that can be reliably used to predict improvement of mitral regur-
gitation following isolated aortic valve intervention has yet to be
equivocally defined.11 19 Therefore, in patients with mitral
regurgitation, special precautions should be taken to avoid para-
valvular aortic regurgitation and resulting combined volume
overload following the procedure.
Of notice, paravalvular leaks were more prevalent following
the use of self-expandable valves as compared with
balloon-expandable valves.20 Moreover, the use of the self-
expandable valves was associated with a less prominent mitral
regurgitation improvement compared with the balloon-expand-
able valves.21 We also observed a greater degree of mitral and
aortic regurgitation postprocedure following self-expandable
valve implantation. It is therefore interesting to note that mitral
valve regurgitation was an independent risk factor for late death
in the registry studies where most patients were treated with the
CoreValve system. This association was much weaker or not
Figure 2 Kaplan–Meier curves demonstrating the association between mitral regurgitation (MR) and mortality in the overall group. (A) No
significant difference in total mortality between patients with significant versus insignificant preprocedural mitral regurgitation (log rank Mantel–Cox
p=0.10); (B) significant difference in mortality in patients in whom preprocedural mitral regurgitation deteriorated versus remained unchanged or
improved at a 1-month follow-up; (C) significant differences in mortality in patients with significant versus insignificant mitral regurgitation
postprocedure and (D) at a 1-month follow-up.















apparent in the registry studies where the CoreValve system was
used in a minority of patients.2 These observations may be
explained by the more frequent adverse interactions between
mitral and aortic regurgitation in patients who received
balloon-expandable valves.
The study limitations
This study has several limitations. While the diagnosis of mitral
and aortic regurgitation criteria was unified throughout the
centres, according to the current guidelines, there was no core
echocardiographic laboratory and quantitative assessment was not
universally unified. The registry did not provide data on the aeti-
ology of concomitant mitral regurgitation, therefore we were not
able to substratify patients according to the mechanism of a
regurgitant jet. The subgroup of patients with concomitant mitral
and aortic regurgitation was limited in number and an analysis
needs to be replicated in the meta-analysis of available data.
Conclusions and practical implications
The current study demonstrated that there was a significant
interaction between the occurrence of paravalvular leak follow-
ing TAVI and persistent mitral regurgitation. Of practical
importance while there was a significant difference in mortality
between patients with significant versus insignificant aortic
regurgitation immediately postprocedure, this difference was no
longer apparent in a subgroup of patients without significant
mitral regurgitation postprocedure. Conversely, significant mitral
regurgitation, as expected, exerted an impact on mortality but
Figure 3 Kaplan–Meier curves demonstrating the relationship between mitral regurgitation (MR) and aortic regurgitation (AR) postprocedure. (A)
Significant difference in mortality between patients with significant versus insignificant AR immediately postprocedure; (B) no difference in mortality
between patients with significant versus insignificant AR postprocedure in a subgroup of patients without significant MR postprocedure; (C) no
difference in mortality between patients with significant versus insignificant MR postprocedure in a subgroup of patients without significant AR
postprocedure; (D) significant difference in mortality in patients with associated mitral and AR postprocedure.
Table 3 Univariate Cox proportionate hazards modelling
Covariate OR 95% CI p Value
Concomitant significant mitral and aortic
regurgitation postprocedure
2.45 1.37 to 4.34 0.002
Significant mitral regurgitation at 1-month
follow-up
2.54 1.09 to 5.89 0.03
New York Heart Association Class III or IV 5.22 1.26 to 21.65 0.02
Significant aortic regurgitation postprocedure 2.84 1.25 to 6.44 0.01
Significant mitral regurgitation postprocedure 2.54 1.10 to 5.89 0.03
Ejection fraction <0.50 1.89 1.02 to 3.60 0.045
EuroSCORE II 1.05 1.01 to 1.09 0.01
Systolic pulmonary artery pressure 1.03 1.001 to 1.06 0.04















this difference was not apparent in a subgroup of patients
without significant aortic regurgitation. Concomitant significant
mitral and aortic regurgitation postprocedure led to a significant
increase in mortality, independent of other risk factors. It
remains to be established whether in patients for whom a percu-
taneous approach is chosen, preprocedural mitral regurgitation
should influence the prosthesis choice. Undoubtedly, it warrants
consideration of managing physicians since clearly, patients with
significant paravalvular leak following TAVI in whom significant
mitral regurgitation persists or worsens are at greater risk of
haemodynamic complications and have a worse midterm prog-
nosis. In such patients, a second step intervention—either a
paravalvular leak closure or percutaneous edge-to-edge mitral
valve repair (or both)—should be considered by a multidisciplin-
ary heart team.
Key messages
What is already known on this subject?
In some patients, significant preprocedural mitral regurgitation
(MR) improves while in the others, it worsens following
transcatheter aortic valve implantation (TAVI). Persistent
significant MR may be especially important in patients who
develop a significant paravalvular leak.
What might this study add?
It demonstrated that there was a significant interaction between
the presence of a paravalvular leak and persistent MR
postprocedure that led to an increased mortality independent of
other risk factors. Of importance however, significant MR had
no impact on mortality in a subgroup of patients without
significant aortic regurgitation and significant paravalvular leak
had no impact on mortality in a subgroup of patients without
significant MR.
How might this impact on clinical practice?
The results of the study may influence management approach to
paravalvular leaks following TAVI, depending on the presence or
absence of significant MR postprocedure.
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